Skip to content

Discontinued — last reported Q1 '25

D&A at other companies

Baxter International logo
Baxter InternationalBAX
$237M-4.0%
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
$4.22M+57.1%
DuPont de Nemours, Inc. logo
DuPont de Nemours, Inc.DD
$68M-9.3%
IR
Ingersoll RandIR
$107.5M+17.7%
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
Nordson logo
NordsonNDSN

Segments

By segment

See full
Pharma$35.64M+14.4%
Beauty$24.72M+23.2%
Closures$14.22M+4.8%

Other financials

Income statement

See full
Revenue$982.9M+10.8%
Gross profit$351.9M+4.6%
Operating income$107.5M-5.2%
Net income$72.7M-7.8%
EPS (diluted)$1.12-4.3%

Balance sheet

See full
Cash & equivalents$225.0M+78.8%
Total debt$1.4B+32.7%
Total equity$2.6B+3.6%
Total assets$5.1B+12.6%

Cash flow

See full
Operating cash flow$118.7M+43.5%
CapEx$65.4M+15.0%
Free cash flow$53.3M+106%

Valuation

See full
Market cap$7.68B-17.9%
Enterprise value$8.89B-13.9%
P/E19.9×-5.4×
P/S-0.6×

Profitability

See full
Gross margin36.7%-1.6pp
Operating margin12.8%-1.2pp
Net margin10%-0.4pp
FCF margin8.4%-2.1pp

Returns & leverage

See full
Return on equity15%-0.2pp
Debt / equity0.5×+0.1×
Current ratio1.7×+0.4×

Where this comes from

Reported directly by AptarGroup in its filing.

Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.

The official record: AptarGroup’s 10-Q, filed May 2, 2025, on SEC EDGAR. View the filing →

Ask your AI about AptarGroup's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AptarGroup's D&A?
AptarGroup (ATR) reported D&A of $65.65M in Q1 2025.
How has AptarGroup's D&A changed year-over-year?
AptarGroup's D&A increased by 2.0% year-over-year, from $64.35M to $65.65M.
What is the long-term trend for AptarGroup's D&A?
Over 3 years (2021 to 2024), AptarGroup's D&A has grown at a 3.9% compound annual growth rate (CAGR), from $234.85M to $263.78M.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.